ArticleEndocrine2017
Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
Daniel Barretto Kendler et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it